European CHMP recommends license extension of pembrolizumab (Keytruda) for oesophageal or gastroesophageal junction adenocarcinoma

The proposed license extension is in combination with platinum and fluoropyrimidine based chemotherapy for first-line treatment of locally advanced or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in tumours expressing PD‑L1.

Source:

European Medicines Agency